Thursday, July 29

Universidad de Oxford

ensayos, Fase I, Noticias, pruebas, Reino Unido, Salud, SIDA, Universidad de Oxford, vacuna, vih

Oxford University Starts HIV Vaccine Trials | Digital Trends Spanish

Researchers at the University of Oxford began phase I trials of a novel vaccine targeting a "wide range" of HIV variants. The HIV-CORE 0052 trial is part of the European AIDS Vaccine Initiative, and will involve 13 healthy, HIV-negative adults between 18 and 65 years of age, who are not considered to be at high risk of infection. Thus, participants will receive a dose of the vaccine, known as HIVconsvC, followed by another booster dose at four weeks. How does it work? Unlike other vaccine candidates, HIVconsvX is designed to induce immune system T lymphocytes and target highly conserved and vulnerable regions of HIV. “An effective vaccine against HIV has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy both in HIV-negative ind...
AstraZeneca, coronavirus, Covid 19, cura efectiva, distribucion, dosis, ensayos clinicos, fase avanzada, Noticias, pacientes, pandemia, Salud, Universidad de Oxford, vacuna, vacuna de oxford, verificación

AstraZeneca reports on distribution of its vaccine | Digital Trends Spanish

Josep Baselga is the director of AstraZeneca's Oncology Research and Development area. In conversation with Spanish media, the professional has ensured that the vaccine developed by the pharmaceutical company against COVID-19 could be in an advanced distribution phase at the end of the first quarter of next year. Baselga has pointed out that by early 2021, the company would have some three billion doses of vaccines that it hopes can be verified as effective. The difficult thing, in this case, would be to find a practical and effective way to distribute them due to the high demand that will exist. For its part, AstraZeneca hopes that before the end of this year, some of the four vaccines it is experimenting with will start to show results. Shutterstock. It is estimated that this vac...
AstraZeneca, coronavirus, Covid 19, enfermedades zoonóticas, Noticias, Salud, Universidad de Oxford

Scientist predicts new viruses transmitted by animals | Digital Trends Spanish

The hope of much of the planet for a vaccine against the coronavirus rests on the shoulders of scientists such as Professor Sarah Gilbert of the University of Oxford, who is leading one of the most promising trials. The British institution works in conjunction with its pharmaceutical partner AstraZeneca. It is currently awaiting the results of phase 3 trials. If they demonstrate a high level of efficacy, the vaccine could be available by the end of 2020. But COVID-19 and its vaccine could be just part of the beginning of a cycle of dangerous new diseases, Sarah Gilbert said in an interview conducted by The Independent. As an authorized voice in health, the scientist warns that new outbreaks of diseases transmitted from animals to humans will appear in the coming years....
AstraZeneca, coronavirus, Covid 19, México y Argentina, Noticias, Producción de vacuna, Salud, Universidad de Oxford

Mexico and Argentina will produce vaccine against COVID-19 for Latin America | Digital Trends Spanish

After Russia became the first country to grant regulatory approval to a vaccine against COVID-19, and with the "impatient" wait for the WHO to analyze the results of its clinical tests, this Wednesday, August 12, it emerged that Mexico and Argentina will contribute to the production of the AstraZeneca vaccine for Latin America. “The laboratory (AstraZeneca) has signed an agreement with the Carlos Slim Foundation (Mexico) to produce between 150 and 250 million vaccines destined for all of Latin America —with the exception of Brazil—, which will be available by the first half of 2021 and that will be distributed equitably among the countries that demand it ”, explained Alberto Fernández, president of Argentina. Pexels The president recalled that the possible vaccine, deve...